Prodrug-tethered lipid nanoparticles for synergistic messenger RNA cancer immunotherapy - PubMed
3 hours ago
- #lipid nanoparticles
- #mRNA delivery
- #cancer immunotherapy
- Prodrug-tethered lipid nanoparticles (pLNPs) enhance messenger RNA (mRNA) cancer immunotherapy by co-delivering IL-12 mRNA and an IDO inhibitor.
- The lead prodrug ionizable lipid (pIL) improves mRNA transfection efficiency and has strong immunomodulatory effects.
- In a mouse model, pLNPs caused complete regression of primary tumors by increasing effector T cell infiltration and reducing exhaustion.
- pLNPs also induced a memory T cell response and systemic immune response, leading to regression of distal tumors.
- The study highlights the potential of pLNPs for combination small-molecule drug and mRNA cancer immunotherapy.